Docality.com Logo
 
Dr. Nivedita  Sharma  Md image

Dr. Nivedita Sharma Md

19 N County Line Rd
Jackson NJ 08527
732 018-8880
Medical School: Other - 1996
Accepts Medicare: Yes
Participates In eRX: Yes
Participates In PQRS: No
Participates In EHR: Yes
License #: 25MA07276900
NPI: 1932134855
Taxonomy Codes:
207R00000X

Request Appointment Information

Awards & Recognitions

About Us

Practice Philosophy

Conditions

Dr. Nivedita Sharma is associated with these group practices

Procedure Pricing

HCPCS Code Description Average Price Average Price
Allowed By Medicare
HCPCS Code:99291 Description:Critical care first hour Average Price:$300.00 Average Price Allowed
By Medicare:
$227.50
HCPCS Code:99223 Description:Initial hospital care Average Price:$250.00 Average Price Allowed
By Medicare:
$205.40
HCPCS Code:99239 Description:Hospital discharge day Average Price:$150.00 Average Price Allowed
By Medicare:
$109.04
HCPCS Code:G0180 Description:MD certification HHA patient Average Price:$90.00 Average Price Allowed
By Medicare:
$56.90
HCPCS Code:99309 Description:Nursing fac care subseq Average Price:$125.00 Average Price Allowed
By Medicare:
$91.97
HCPCS Code:G0179 Description:MD recertification HHA PT Average Price:$75.00 Average Price Allowed
By Medicare:
$44.30
HCPCS Code:99335 Description:Domicil/r-home visit est pat Average Price:$125.00 Average Price Allowed
By Medicare:
$95.97
HCPCS Code:99212 Description:Office/outpatient visit est Average Price:$75.00 Average Price Allowed
By Medicare:
$46.08
HCPCS Code:99204 Description:Office/outpatient visit new Average Price:$200.00 Average Price Allowed
By Medicare:
$171.58
HCPCS Code:99305 Description:Nursing facility care init Average Price:$160.00 Average Price Allowed
By Medicare:
$132.77
HCPCS Code:99235 Description:Observ/hosp same date Average Price:$200.00 Average Price Allowed
By Medicare:
$173.31
HCPCS Code:99232 Description:Subsequent hospital care Average Price:$100.00 Average Price Allowed
By Medicare:
$73.38
HCPCS Code:99213 Description:Office/outpatient visit est Average Price:$100.00 Average Price Allowed
By Medicare:
$75.68
HCPCS Code:G0438 Description:PPPS, initial visit Average Price:$200.00 Average Price Allowed
By Medicare:
$178.40
HCPCS Code:69210 Description:Remove impacted ear wax Average Price:$75.00 Average Price Allowed
By Medicare:
$55.50
HCPCS Code:36415 Description:Routine venipuncture Average Price:$20.00 Average Price Allowed
By Medicare:
$3.00
HCPCS Code:93000 Description:Electrocardiogram complete Average Price:$35.00 Average Price Allowed
By Medicare:
$20.80
HCPCS Code:96372 Description:Ther/proph/diag inj sc/im Average Price:$40.00 Average Price Allowed
By Medicare:
$26.58
HCPCS Code:99214 Description:Office/outpatient visit est Average Price:$125.00 Average Price Allowed
By Medicare:
$111.64
HCPCS Code:93005 Description:Electrocardiogram tracing Average Price:$25.00 Average Price Allowed
By Medicare:
$11.85
HCPCS Code:93227 Description:Ecg monit/reprt up to 48 hrs Average Price:$40.00 Average Price Allowed
By Medicare:
$28.01
HCPCS Code:J3420 Description:Vitamin b12 injection Average Price:$5.00 Average Price Allowed
By Medicare:
$0.52
HCPCS Code:85610 Description:Prothrombin time Average Price:$10.00 Average Price Allowed
By Medicare:
$5.56
HCPCS Code:G0008 Description:Admin influenza virus vac Average Price:$30.00 Average Price Allowed
By Medicare:
$26.58
HCPCS Code:G0009 Description:Admin pneumococcal vaccine Average Price:$30.00 Average Price Allowed
By Medicare:
$26.58
HCPCS Code:90670 Description:Pneumococcal vacc 13 val im Average Price:$140.00 Average Price Allowed
By Medicare:
$137.29
HCPCS Code:Q2039 Description:NOS flu vacc, 3 yrs & >, im Average Price:$15.00 Average Price Allowed
By Medicare:
$13.30

HCPCS Code Definitions

99213
Office or other outpatient visit for the evaluation and management of an established patient, which requires at least 2 of these 3 key components: An expanded problem focused history; An expanded problem focused examination; Medical decision making of low complexity. Counseling and coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of low to moderate severity. Typically, 15 minutes are spent face-to-face with the patient and/or family.
G0008
Administration of influenza virus vaccine
G0438
Annual wellness visit; includes a personalized prevention plan of service (pps), initial visit
99212
Office or other outpatient visit for the evaluation and management of an established patient, which requires at least 2 of these 3 key components: A problem focused history; A problem focused examination; Straightforward medical decision making. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are self limited or minor. Typically, 10 minutes are spent face-to-face with the patient and/or family.
G0180
Physician certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians to affirm the initial implementation of the plan of care that meets patient's needs, per certification period
G0179
Physician re-certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians to affirm the initial implementation of the plan of care that meets patient's needs, per re-certification period
G0009
Administration of pneumococcal vaccine
99204
Office or other outpatient visit for the evaluation and management of a new patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; Medical decision making of moderate complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of moderate to high severity. Typically, 45 minutes are spent face-to-face with the patient and/or family.
96372
Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular
Q2039
Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (not otherwise specified)
99214
Office or other outpatient visit for the evaluation and management of an established patient, which requires at least 2 of these 3 key components: A detailed history; A detailed examination; Medical decision making of moderate complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of moderate to high severity. Typically, 25 minutes are spent face-to-face with the patient and/or family.
J3420
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg
99335
Domiciliary or rest home visit for the evaluation and management of an established patient, which requires at least 2 of these 3 key components: An expanded problem focused interval history; An expanded problem focused examination; Medical decision making of low complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of low to moderate severity. Typically, 25 minutes are spent with the patient and/or family or caregiver.
99305
Initial nursing facility care, per day, for the evaluation and management of a patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; and Medical decision making of moderate complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the problem(s) requiring admission are of moderate severity. Typically, 35 minutes are spent at the bedside and on the patient's facility floor or unit.
99232
Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: An expanded problem focused interval history; An expanded problem focused examination; Medical decision making of moderate complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the patient is responding inadequately to therapy or has developed a minor complication. Typically, 25 minutes are spent at the bedside and on the patient's hospital floor or unit.
99309
Subsequent nursing facility care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: A detailed interval history; A detailed examination; Medical decision making of moderate complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the patient has developed a significant complication or a significant new problem. Typically, 25 minutes are spent at the bedside and on the patient's facility floor or unit.
99223
Initial hospital care, per day, for the evaluation and management of a patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; and Medical decision making of high complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the problem(s) requiring admission are of high severity. Typically, 70 minutes are spent at the bedside and on the patient's hospital floor or unit.
69210
Removal impacted cerumen requiring instrumentation, unilateral
99291
Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes
99235
Observation or inpatient hospital care, for the evaluation and management of a patient including admission and discharge on the same date, which requires these 3 key components: A comprehensive history; A comprehensive examination; and Medical decision making of moderate complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually the presenting problem(s) requiring admission are of moderate severity. Typically, 50 minutes are spent at the bedside and on the patient's hospital floor or unit.
99239
Hospital discharge day management; more than 30 minutes
93000
Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report
93227
External electrocardiographic recording up to 48 hours by continuous rhythm recording and storage; review and interpretation by a physician or other qualified health care professional
93005
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report

Medical Malpractice Cases

None Found

Medical Board Sanctions

None Found

Referrals

NPI
Doctor Name
Specialty
Count
1821029745
Infectious Disease
4,268
1053373613
Physical Medicine And Rehabilitation
3,885
1447276233
Geriatric Medicine
3,431
1801979901
Cardiovascular Disease (Cardiology)
2,691
1548278039
Diagnostic Radiology
2,634
1134113376
Hematology/Oncology
2,371
1164440053
Diagnostic Radiology
2,065
1114949674
Diagnostic Radiology
2,060
1427070069
Diagnostic Radiology
1,756
1144242686
Diagnostic Radiology
1,718
*These referrals represent the top 10 that Dr. Sharma has made to other doctors

Publications

A study on characterization of new bacteriocin produced from a novel strain of Lactobacillus spicheri G2 isolated from Gundruk- a fermented vegetable product of North East India: A novel bacteriocin production from Lactobacillus spicheri G2. - Journal of food science and technology
Bacteriocin producing Lactobacillus spicheri G2, isolated from Gundruk - a traditional fermented vegetable product of North East India. L. spicheri G2 identified by morphological, biochemical techniques followed by 16S rRNA gene technique. The 16Sr RNA sequence of bacteriocin producer is registered in NCBI under accession no. JX481912. The bacteriocin producing potential of L. spicheri is being reported for the first time in the present investigation. Bacteriocin of L. spicheri G2 showed strong antagonism against food spoiling and pathogenic bacteria viz. Listeria monocytogenes, Staphlococcus aureus, Clostridium perfringens, Streptococcus mutans, Lactobacillus plantarum, Leuconostoc mesenteroides and Bacillus cereus. Bacteriocin production of L. spicheri G2 was enhanced by optimization of production time, pH of medium and incubation temperature by following one variable at a time method. Maximum bacteriocin activity (2000 AU/ml) was recorded in MRS broth at 34 h with an initial pH of 4.0 after incubating at 35 °C. The bacteriocin was purified by single step gel exclusion chromatography. Molecular weight of this novel bacteriocin was determined by SDS PAGE which was found to be 43 kDa. Purified bacteriocin was found resistant to high temperature and varied pH range but sensitive to proteolytic enzymes like trypsin and proteinase k, the characters desirable for food preservation.
Clinicoinvestigational and demographic profile of children with thalassemia major. - Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion
There are an estimated 200 million carriers of the β-thalassemia gene worldwide, 20 million being in India. The mean prevalence in India is 3.3 %. Objective To evaluate the clinico-investigational profile and the demographic characteristics of patients with thalassemia major (TM). Methods This was a retrospective analysis of the clinico-demographic profile at presentation of patients of TM diagnosed in the Paediatric Hematology Clinic of our hospital. Results The clinical profile of 964 patients of TM was analyzed. The mean age at presentation of untransfused children was 13.2 ± 9.7 months. Nearly 2/3(rd) children presented before 1 year of age. Almost 40 % had symptoms for 3 months prior to presentation. The manifestations at presentation included pallor and failure to thrive. About 40 % presented with severe anemia, with a hemoglobin of <5.0 gm/dl. A large number received blood transfusions prior to establishment of the diagnosis. Half of the families had ancestors who hailed originally from Pakistan. Approximately 50 % belonged to the Khatri/Arora castes. The parental literacy rate was about 90 %. Conclusions Thalassemia needs greater public awareness and prevention strategies in our country. Some communities are at high risk as compared to others. Education programs and compulsory antenatal screening appear to be the order of the day.
Expression of estrogen receptor β and Ki 67 in benign & malignant human prostate lesions by immunohistochemistry. - Pathology oncology research : POR
Estrogen regulates the growth of prostate through two receptors Estrogen receptor α & β of which ERβ is proposed to be antiproliferative. There is a wide variation in the results of various studies regarding the localisation, level of expression of ERβ in benign & malignant lesions of prostate and its relation to the grade of tumor emphasizing the need for additional studies to standardize the distribution of this receptor in prostate. This was a prospective study conducted in Department of Pathology, UCMS, Delhi, evaluating ERβ & Ki 67 immunoexpression in 60 cases of benign and malignant lesions of prostate (30 each). Tissue for study included prostatic core biopsy and TURP chips. After histomorphological diagnosis, immunohistochemical staining was performed using a monoclonal antibody. Nuclear expression of ERβ & Ki67 was evaluated and compared between the two study groups (benign & malignant lesions) using Pearson chi square test. ERβ was predominantly localized to nuclei of secretory epithelium of prostatic glands. Expression of ERβ was higher in benign glands compared to carcinoma. However, majority of carcinomas retained ERβ expression though at much lower levels. Expression of Ki 67 was higher in carcinoma than benign hyperplasia. There was no correlation between the ERβ status, Ki 67 expression & grade of tumor. Expression of ERβ is downregulated in carcinoma compared to benign hyperplasia and is consistent with its chemopreventive role in prostate. It might have a therapeutic implication as agonists' targeting this receptor could be a part of treatment protocol for those patients of carcinoma who retain this receptor at significant levels.
Characterization of Bacteriocin like inhibitory substance produced by a new Strain Brevibacillus borstelensis AG1 Isolated from 'Marcha'. - Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology]
In the present study, a bacterium isolated from Marcha- a herbal cake used as traditional starter culture to ferment local wine in North East India, was evaluated for bacteriocin like inhibitory substance production and was tested against six food borne/spoilage causing pathogens viz. Listeria monocytogenes MTCC 839, Bacillus subtilis MTCC 121, Clostridium perfringens MTCC 450, Staphylococcus aureus, Lactobacillus plantarum and Leuconostoc mesenteroides MTCC 107 by using bit/disc method followed by well diffusion method. The bacterial isolate was identified as Brevibacillus borstelensis on the basis of phenotypic, biochemical and molecular characteristics using 16Sr RNA gene technique. Bacteriocin like inhibitory substance produced by Brevibacillus borstelensis AG1 was purified by gel exclusion chromatography. The molecular mass of the Brevibacillus borstelensis AG1 was found to be 12 kDa. Purified bacteriocin like inhibitory substance of Brevibacillus borstelensis was further characterized by studying the effect of temperature, pH, proteolytic enzyme and stability. Bacteriocin like inhibitory substance was found to be thermostable upto 100 °C, active at neutral pH, sensitive to trypsin, and partially stable till third week of storage thus showing a bright prospective to be used as a potential food biopreservative.
Clinical and demographic profile of snake envenomation in himachal pradesh, India. - Indian pediatrics
We describe profile of 60 children [mean (SD) age, 9.5 (3.8) y] presenting to the department of Pediatrics with snake envenomation. Neurotoxic bites were predominant (53%) and required mean (SD) 21.5 (9.29) antisnake venom vials, while children with neurohemotoxic features required mean (SD) 31.2 (10.8) vials to improve. Duration of hospital stay was median (SD) 4.0 (2.71) days. The commonest complication was respiratory dysfunction; mortality rate was 13.3%.
Purification and Characterization of Bacteriocin Produced by Lactobacillus brevis UN Isolated from Dhulliachar: a Traditional Food Product of North East India. - Indian journal of microbiology
A bacteriocin producing strain Lactobacillus brevis UN isolated from Dulliachar-a salted pickle and identified by biochemical and molecular methods. L. brevis UN was found to produce bacteriocin with broad spectrum activity against spoilage causing/food borne pathogens viz. L. monocytogenes, C. perfringens, S. aureus, L. mesenteroides, L. plantarum and B. cereus. Bacteriocin production was optimized through classical one variable at a time method. The isolate showed maximum bacteriocin production at early stationary phase, pH 4.0, temperature 35 °C and with an inoculum size of 1.5 OD @ 10 %. Bacteriocin produced by L. brevis UN was purified to homogeneity by single step gel exclusion chromatography and was most active at pH 6.0 and 7.0, stable up to 100 °C and was proteinaceous in nature. The results of NMR revealed the presence of proline, glutamic acid, aspartic acid, leucine, isoleucine and serine in its peptide structure. PCR amplification analysis determined that bacteriocin encoded gene in L. brevis UN was plasmid bound.
Gene environment interaction in urinary bladder cancer with special reference to organochlorine pesticide: a case control study. - Cancer biomarkers : section A of Disease markers
Urinary bladder cancer (UBC) is a common disease worldwide with a higher incidence rate in developed countries. Organochlorine pesticides (OCPs), potent endocrine disrupters, are found to be associated with several cancers such as prostate, breast, bladder, etc. Glutathione S-transferase (GST) is a polymorphic supergene family involved in the detoxification of numerous environmental toxins including OCPs. The present study was carried out in UBC subjects (n=50) and healthy control subjects (n=50) with an aim to determine the role of GSTM1 and GSTT1 polymorphism and its implication on the OCP detoxification or bioaccumulation which may increase the risk of UBC in humans. This study was also designed to identify the "gene-environment interaction" specifically between gene polymorphism in xenobiotic metabolizing genetic enzyme(s) and blood OCP levels. GSTM1/GSTT1 gene polymorphism was analysed by using multiplex PCR. OCPs levels in whole blood were estimated by Gas chromatography equipped with electron capture detector. The results demonstrated a significant (p< 0.05) increase in frequency of GSTM1^{-}/GSTT1^{-} (null) genotype in UBC cases without interfering the distribution of other GSTT1/GSTM1 genotypes. The blood levels of alpha (α), Beta (β), Gamma (γ), total - Hexachlorcyclohexane (HCH) and para-para - dichlorodiphenyltrichloroetane (p,p'-DDT) were found to be significantly (p< 0.05) high in UBC cases as compared to controls. Multiple regression analysis revealed a significant interaction between β-HCH and GSTM1^{-} genotype (p< 0.05) as well as in β-HCH and GSTT1^{-} genotype (p< 0.05) respectively. These findings indicate that "gene-environment interaction" may play a key role in increasing the risk for UBC in individuals who are genetically more susceptible due to presence of GSTM1/GSTT1 null deletion during their routine encounter with or exposure to OCPs.
A biodegradation study of forest biomass by Aspergillus niger F7: correlation between enzymatic activity, hydrolytic percentage and biodegradation index. - Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology]
Aspergillus niger F7 isolated from soil was found to be the potent producer of cellulase and xylanase. The residue of forest species Toona ciliata, Celtris australis, Cedrus deodara and Pinus roxburghii was selected as substrate for biodegradation study due to its easy availability and wide use in industry. It was subjected to alkali (sodium hydroxide) treatment for enhancing its degradation. Biodegradation of forest waste by hydrolytic enzymes (cellulase and xylanase) secreted by A. niger under solid state fermentation (SSF) was explored. SSF of pretreated forest biomass was found to be superior over untreated forest biomass. Highest extracellular enzyme activity of 2201±23.91 U/g by A. niger was shown in pretreated C. australis wood resulting in 6.72±0.20 percent hydrolysis and 6.99±0.23 biodegradation index (BI). The lowest BI of 1.40±0.08 was observed in untreated saw dust of C. deodara having the least enzyme activity of 238±1.36 U/g of dry matter. Biodegradation of forest biomass under SSF was increased many folds when moistening agent i.e. tap water had been replaced with modified basal salt media (BSM). In BSM mediated degradation of forest waste with A. niger, extracellular enzyme activity was increased up to 4089±67.11 U/g of dry matter in turn resulting in higher BI of 15.4±0.41 and percent hydrolysis of 19.38±0.81 in pretreated C. australis wood. A. niger exhibited higher enzyme activity on pretreated biomass when moistened with modified BSM in this study. Statistically a positive correlation has been drawn between these three factors i.e. enzyme activity, BI and percent hydrolysis of forest biomass thus proving their direct relationship with each other.
Cutaneous Rosai-Dorfman disease: presenting as massive bilateral eyelid swelling. - Pediatric dermatology
Rosai-Dorfman disease is a rare, benign histiocytic proliferative disorder, which commonly affects the lymph nodes. Cutaneous Rosai-Dorfman disease is a rare form of Rosai-Dorfman disease limited to the skin. We report a case of cutaneous Rosai-Dorfman presenting with bilateral eyelid swelling in a child.
Purification and characterization of bacteriocin produced by strain of Lactobacillus brevis MTCC 7539. - Indian journal of biochemistry & biophysics
Bacteriocin, an antimicrobial agent having potential for food biopreservation was purified from Lactobacillus brevis (a safe food-grade bacteria isolated from Vari Kandal, a traditional fermented food of Himachal Pradesh by adopting a novel repeated washing method. Its purity was confirmed by SDS-PAGE and Native-PAGE. The relative molecular mass of bacteriocin was 93.74 kD, while specific activity and recovery were 35.52 folds and 17.13%, respectively. It showed high thermal stability and was active over wide range of pH and exhibited sensitivity to trypsin.

Map & Directions

19 N County Line Rd Jackson, NJ 08527
View Directions In Google Maps

Nearby Doctors

255 S New Prospect Rd
Jackson, NJ 08527
732 671-1099
1102 Bennetts Mills Rd
Jackson, NJ 08527
732 011-1970
12 Fox Hollow Dr
Jackson, NJ 08527
908 554-4200
25 N County Line Rd
Jackson, NJ 08527
732 059-9855
100 W Veterans Hwy
Jackson, NJ 08527
732 827-7770
975 Bennetts Mills Rd
Jackson, NJ 08527
732 631-1411
999 Bennetts Mills Rd
Jackson, NJ 08527
732 678-8989
688 Brewers Bridge Rd
Jackson, NJ 08527
732 426-6900
19 N County Line Rd
Jackson, NJ 08527
732 320-0935
31 Bridgewater Ct
Jackson, NJ 08527
732 427-7863